2024
Efficacy and utility of antifibrinolytics in pediatric spine surgery: a systematic review and network meta-analysis
Aghajanian S, Mohammadifard F, Kohandel Gargari O, Naeimi A, Bahadorimonfared A, Elsamadicy A. Efficacy and utility of antifibrinolytics in pediatric spine surgery: a systematic review and network meta-analysis. Neurosurgical Review 2024, 47: 177. PMID: 38644447, DOI: 10.1007/s10143-024-02424-x.Peer-Reviewed Original ResearchConceptsNetwork meta-analysisRate of complicationsBlood lossSpine surgeryEpsilon-aminocaproic acidMeta-analysisTranexamic acidEfficacy of antifibrinolyticsPediatric spine surgeryPerioperative blood lossReduce blood lossStandardized outcome dataRandomized clinical trialsStandard of carePerioperative bleedingTransfusion volumeTransfusion rateAntifibrinolytic agentsMassive transfusionPediatric patientsSafety profilePediatric surgeryProbability of efficacyAntifibrinolyticsClinical trials
2023
A current review of spinal meningiomas: epidemiology, clinical presentation and management
Elsamadicy A, Reeves B, Craft S, Sherman J, Koo A, Sayeed S, Sarkozy M, Kolb L, Lo S, Shin J, Sciubba D, Mendel E. A current review of spinal meningiomas: epidemiology, clinical presentation and management. Journal Of Neuro-Oncology 2023, 161: 395-404. PMID: 36637710, DOI: 10.1007/s11060-023-04238-1.Peer-Reviewed Original ResearchConceptsSpinal meningiomasClinical presentationTumor developmentAdverse postoperative outcomesBenign spinal tumorsBenign spine tumorsRecent treatment recommendationsCharacteristic imaging findingsSubsequent tumor developmentPostoperative outcomesReceptor statusSpine tumorsImaging findingsSpinal tumorsCase reportTreatment recommendationsClinical evaluationClinical trialsGoogle Scholar searchOperative techniqueIntracranial meningiomasRadiation modalitiesSystematic reviewMeningiomasTumor genetics
2017
Prospect of rindopepimut in the treatment of glioblastoma
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opinion On Biological Therapy 2017, 17: 507-513. PMID: 28274144, PMCID: PMC5787389, DOI: 10.1080/14712598.2017.1299705.Peer-Reviewed Original ResearchConceptsKeyhole limpet hemocyaninClinical efficacyClinical trialsEpidermal growth factor receptor variant IIIPhase III clinical trialsPhase II clinical trialPrimary malignant neoplasmsTreatment of GBMSub-group analysisTumor-specific epitopesTreatment of glioblastomaTumor-specific activityPrimary endpointClinical benefitMalignant neoplasmsPeptide vaccineInhibition of apoptosisSignificant efficacyGBM therapyRindopepimutAmino acid peptideLimpet hemocyaninVariant IIIGBM cellsEGFRvIII mutationThe Safety of available immunotherapy for the treatment of glioblastoma
Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion On Drug Safety 2017, 16: 277-287. PMID: 27989218, PMCID: PMC5404815, DOI: 10.1080/14740338.2017.1273898.Peer-Reviewed Original ResearchConceptsClinical trialsCurrent immunotherapiesCommon malignant primary brain tumorMalignant primary brain tumorAdoptive T-cell immunotherapyReviewed clinical trialsRole of immunotherapyImmune checkpoint blockadeMaximal surgical resectionOngoing clinical trialsPrimary brain tumorsT-cell immunotherapyTreatment of glioblastomaAdjuvant chemoradiationAvailable immunotherapiesCheckpoint blockadeCytokine therapySurgical resectionImmunotherapeutic approachesCell immunotherapyPatient survivalRecurrent glioblastomaVaccination strategiesSafety dataBrain tumors